Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
You can also search for this author in PubMed Google Scholar
The US FDA approved Provention Bio’s teplizumab to delay the onset of type 1 diabetes — a win for an immunomodulating drug that has spent over 20 years in the clinic.
Subscribe to Journal
Get full journal access for 1 year
73,83 €
only 6,15 € per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
doi: https://doi.org/10.1038/d41573-022-00198-9
Oklahoma Medical Research Foundation (OMRF)
Oklahoma City, United States
Oklahoma Medical Research Foundation (OMRF)
Oklahoma City, United States
Oklahoma Medical Research Foundation (OMRF)
Oklahoma City, United States
Oklahoma Medical Research Foundation (OMRF)
Oklahoma City, United States
An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.
© 2023 Springer Nature Limited